Urologic Indications of Gemcitabine:
In metastatic bladder cancer (urothelial carcinoma) (Opens in a new window), gemcitabine is combined with cisplatin. For patients ineligible for cisplatin, substitution with carboplatin is used with somewhat lower efficacy.
Neoadjuvant or adjuvant chemotherapy of bladder cancer (Opens in a new window) or upper tract urothelial carcinoma in combination with cisplatin before or after curative surgery (cystectomy (Opens in a new window) or nephroureterectomy (Opens in a new window)).
Off-label use in Europe: intravesical therapy of non-muscle invasive high-grade bladder cancer (Opens in a new window) after BCG failure, sometimes in combination with docetaxel (Opens in a new window). In the United States, since 2025, an intravesical gemcitabine delivery system (Inlexzo) has marketing authorization, which releases the drug over three weeks (Daneshmand et al., 2025).
Date
November 4, 2025
0 comments
Would you like to be the first to write a comment?
Become a member of urology-textbook.com and start the conversation.
